Disclaimer

This presentation has been prepared by Ellex Medical Lasers Ltd (Ellex).
While the information in this presentation has been prepared in good faith and with reasonable care, no representation or warranty, express or implied, is made as to the accuracy, adequacy or reliability of any statement, estimates, opinions or other information contained in the presentation.

This presentation may contain forward looking statement. These forward-looking statement have been made based upon Ellex’s expectations and beliefs concerning future developments and their potential effect on Ellex (and it’s controlled entities) and are subject to risks and uncertainty which are, in many instances, beyond Ellex’s control. No assurance is given that future developments will be in accordance with Ellex’s expectations. Actual results could differ materially from those expected by Ellex.

This presentation does not constitute an offer to sell or a solicitation of an offer to purchase any security or financial product or service. Any such offer or solicitation shall be made only pursuant to a Product Disclosure Statement, Information Memorandum, Prospectus or other offer document relating to a financial product or service.
Past performance is not necessarily indicative of future results and no person guarantees the performance of any financial product or service or the amount or timing of any return from it. There can be no assurance that the financial product or service will achieve any targeted return, that asset allocations will be met or that the financial product or service will be able to implement its investment strategy and investment approach or achieve its investment objective.

The information contained in this presentation is not intended to be relied upon as advice to investors or potential investors, who should consider seeking independent professional advice depending upon their specific investment objectives, financial situation or particular needs.
Highlights of Ellex

• Ellex is a world leader in ophthalmology with number one market share in ophthalmic lasers, a 30+ year operating history and well recognized and trusted global brand
• Ellex has a seasoned senior management team with members showing at least 20 years of experience in the ophthalmic space
• Ellex iTrack™ is a unique, patent-protected micro-catheter for treating glaucoma, manufactured in the United States, currently experiencing 71\(^{(1)}\)% growth in USA sales
• Ellex 2RT® is a potentially game changing, minimally invasive, painless interventional treatment for early to intermediate AMD
• Ellex 2RT® clinical trial data expected mid-2018 from a 3 year sham controlled trial (6 years from first enrolment)
• Ellex core business produces lasers & ultrasound products that are used daily by ophthalmologists worldwide and has grown at a revenue CAGR of 8\(^{(2)}\)% from 2013 to 2017, significantly outpacing the market growth rate of 3\(^{(3)}\).

---

(1) Q1 Fiscal year 2018 compared with Q1 Fiscal year 2017
(2) Based on Ellex data
(3) MarketScope "2017 Ophthalmic Lasers Report"
Ellex – a global brand in ophthalmology

A world leader in ophthalmology is leveraging its long operating history and global brand with two transformational products targeting material revenue growth

<table>
<thead>
<tr>
<th>Segment</th>
<th>Revenue FY17 (A$M)</th>
<th>EBITDA $Am/(loss)</th>
<th>Business Model</th>
<th>Current Market Size per annum</th>
<th>Current Estimated Market Growth Rate</th>
<th>Fit with Strategy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ellex core laser &amp; ultrasound</td>
<td>62.5</td>
<td>7.3</td>
<td>Capital equipment sales</td>
<td>US$500m(4)</td>
<td>3%(2)</td>
<td>Strategic revenue base</td>
</tr>
<tr>
<td>Ellex iTrack™ MIGS device</td>
<td>8.2 (run rate A$9.5m)</td>
<td>(1.3)</td>
<td>Consumable product</td>
<td>US$240m(2)</td>
<td>44%(2)</td>
<td>Expected to provide material growth in FY18 and beyond</td>
</tr>
<tr>
<td>Ellex 2RT® for early AMD(1)</td>
<td>0.9</td>
<td>(0.4)</td>
<td>Capital equipment &amp; procedure fee</td>
<td>US$10bn(5)</td>
<td>7.1% growth in pharma(3) spend in 7 major economies</td>
<td>Expected to provide substantial growth opportunity subject to outcome of clinical trial</td>
</tr>
</tbody>
</table>

(1) Subject to outcome of phase III clinical trial reading out in mid 2018. Currently early adopter sales only
(3) Quoted in “Retinal Physician” Jan/Feb 2015 based on data from Global Data
(4) Compilation of sources described on Slide 23
(5) Based on most recent annual reports from Novartis and Bayer
Ellex products target the four major causes of blindness

- **Cataract**
  - 26.2m cataract operations performed per year (almost 100% of the population develops a cataract with age)
  - 89m people worldwide with glaucoma

- **Diabetic Retinal Disease**
  - 109m people worldwide with diabetic retinal disease
  - 109m people worldwide with diabetic retinal disease

- **Early AMD**
  - 153m people with early age-related macular degeneration

- **Glaucoma**
  - 89m people worldwide with glaucoma

**One Powerful Vision**

(1) MarketScope “2017 Ophthalmic Lasers Report”
(2) Refer to sources on Slide 23
Ellex products range

One Powerful Vision

Diagnosis
- Ophthalmic ultrasound

Retinal Disease
- General retinal laser treatments (e.g., PRP)
- Early AMD
- Retinal rejuvenation laser intervention

Glaucoma
- SLT laser therapy
- ABiC with iTrack

Secondary Cataract
- YAG photodisruption laser treatment

Floaters and Vitreous Opacities
- YAG laser vitreolysis treatment

One Powerful Vision
Ellex is a well known Global Brand with Established Distribution Channels

Regional Revenue Contribution FY2017

35%
North America
Minneapolis, MN
Laser & Ultrasound direct sales
Fremont, CA
iTrack headquarters & manufacturing
USA Corporate Office

18%
EMEA
Distributor Sales, Lyon

2%
France
Direct Sales
Lyon
Ellex Customer Service Center and France Sales Subsidiary

5%
Germany
Direct Sales Subsidiary, Berlin

9%
Asia (other than Japan)
Distributor Sales

15%
Japan
Direct Sales Subsidiary, Tokyo

13%
Australia
Direct Sales
Adelaide, Australia
Corporate Head Office
Manufacturing
Asia Customer Support
Ellex iTrack™ a MIGS device that restores the natural biology of the eye

- Ellex iTrack is used in the ABiC (ab interno canaloplasty) procedure
- The Ellex iTrack™ is a unique, patent-protected microcatheter for treating patients with glaucoma
- It is used in an ab interno operation to clear and flush the main ocular drainage systems that are compromised as a result of glaucoma
- Used and reimbursed in the USA with or without concurrent cataract surgery (CPT1 code). Reimbursement in place to hospital/ambulatory surgery centre for facilities and to Surgeon for performing the operation.
- 360° solution clearing Schlemms canal and opening collector channels
- Can be repeated and revitalises natural outflow pathways, leaving nothing behind (US competitors stents)
- Current market accessible for MIGS and canaloplasty devices US$240m growing to US$1373m by 2022 (44% CAGR) (per Marketscope 2017 Glaucoma Surgical Devices Report)
## Ellex iTrack™ and MIGS Competitive Landscape & Doctor Testimonials

<table>
<thead>
<tr>
<th></th>
<th>FDA Approval</th>
<th>Reimbursement</th>
<th>Indicated for Use With Cataract Surgery</th>
<th>Indicated for Use Outside Cataract Surgery</th>
<th>Patient Selection: POAG(1)</th>
<th>Patient Selection: POAG(2)</th>
<th>Method of Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABiC iTrack™ (Ellex)</td>
<td>YES</td>
<td>YES</td>
<td>YES</td>
<td>YES</td>
<td>YES</td>
<td>YES</td>
<td>360° dilation and restoration of natural outflow systems</td>
</tr>
<tr>
<td>iStent (Glaukos)</td>
<td>YES</td>
<td>YES</td>
<td>YES</td>
<td>YES</td>
<td>YES</td>
<td>YES</td>
<td>Single point stents that create artificial outflow pathways</td>
</tr>
<tr>
<td>CyPass Microstent (Alcon)</td>
<td>YES</td>
<td>YES</td>
<td>YES</td>
<td>YES</td>
<td>YES</td>
<td>YES</td>
<td></td>
</tr>
<tr>
<td>XEN Gel Stent (Allergan)</td>
<td>YES</td>
<td>YES</td>
<td>YES</td>
<td>YES</td>
<td>YES</td>
<td>YES</td>
<td></td>
</tr>
</tbody>
</table>

**Doctor Mark Gallardo in “The Ophthalmologist” Magazine – September 2017**

- “ABiC with Ellex iTrack does not have to be coupled with cataract extraction. It can be done in phakic and pseudophakic patients or as an adjunct to cataract extraction.

- It is also not limited to mild-to-moderate disease and could be performed in patients with severe glaucoma (although outcomes may be more variable in such cases).

- Circumnavigation of the canal with the iTrack is the only method that has the ability to lyse all herniations obstructing the collector channels, comprehensively treating the entire conventional outflow system.

- It is less traumatic and disruptive compared to most MIGS procedures – without ablating the TM or inner wall of Schlemm’s canal, ABiC leaves the natural blood-aqueous barrier intact, avoiding the possibility of recurrent hyphema, as seen with some MIGS procedures.”

---

(1) POAG – Primary open angle glaucoma
Extract of Ellex iTrack™ clinical data – 24 months

• Retrospective analysis, single-center, non-randomized study to demonstrate the efficacy and safety of ABiC with Ellex iTrack™ in reducing IOP and glaucoma medication dependence in patients with mild to moderate, uncontrolled POAG over 24 months.

• The analysis also compared the efficacy of ABiC with Ellex iTrack™ in reducing IOP and glaucoma medication dependence between patients undergoing a standalone procedure and patients undergoing a combined procedure of cataract surgery and ABiC.

**TABLE 1: % REDUCTION IN IOP AND MEDICATION USE COMPARED TO BASELINE (see Note 1)**

<table>
<thead>
<tr>
<th></th>
<th>ALL EYES (n=75 pre-op)</th>
<th>CATARACT + ABiC (n=34 pre-op)</th>
<th>STANDALONE ABiC (n=41 pre-op)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>12-month</td>
<td>24-month</td>
<td>12-month</td>
</tr>
<tr>
<td>n (eyes)</td>
<td>73</td>
<td>33</td>
<td>3</td>
</tr>
<tr>
<td>Reduction in IOP (%)</td>
<td>33.68%</td>
<td>39.06%</td>
<td>33.24%</td>
</tr>
<tr>
<td>Reduction in number of medications (%)</td>
<td>60.75%</td>
<td>70.15%</td>
<td>67.05%</td>
</tr>
</tbody>
</table>

Note 1
• Interim data provided courtesy of Mark J. Gallardo, MD. Data unpublished
• Uncontrolled glaucoma.
• “Healon GV” viscoelastic used for canal dilation. Approx. 25 clicks applied
Ellex iTrack™ Financial Performance

• Sales growth in FY17H2 accelerated due to expansion of USA sales team and improvement in reimbursement effective 1 January 2017 (71% growth in FY18 Q1 in USA and globally)
• Good growth in markets outside the US and good initial sales into China

- Reported sales for the year to 30 June 2017 of A$8.2m (year end run rate of A$9.5m)
- Acceleration of annual revenue to 46% above June 2016 annual revenue rate
- USA sales force recruitment, additional marketing, reimbursement increase on 1 January 2017 and initial sales to China drove growth

Sales by Region $Am

<table>
<thead>
<tr>
<th></th>
<th>FY16</th>
<th>FY17 Reported</th>
<th>FY18 Q1</th>
<th>Growth % Q1FY18</th>
</tr>
</thead>
<tbody>
<tr>
<td>USA</td>
<td>3.9</td>
<td>4.7</td>
<td>1.2</td>
<td>+71</td>
</tr>
<tr>
<td>Asia</td>
<td>0.3</td>
<td>1.0</td>
<td>0.2</td>
<td>&gt;100%</td>
</tr>
<tr>
<td>Rest of World</td>
<td>2.2</td>
<td>2.5</td>
<td>0.6</td>
<td>+36%</td>
</tr>
<tr>
<td></td>
<td>6.3</td>
<td>8.2</td>
<td>2.0</td>
<td>+71%</td>
</tr>
</tbody>
</table>
Ellex iTrack™ Global Sales in 3 months to 30 September 2017

Ellex iTrack sales Q1FY18

71% sales growth, globally and USA

Region
- USA
- Europe
- Asia

3 months ended 30 Sept 2016
3 months ended 30 Sept 2017

US$000
Ellex iTrack™ USA Sales 5 quarters of growth

USA iTrack sales by quarter in US$'000's

Quarter

<table>
<thead>
<tr>
<th>Quarter</th>
<th>US$'000's</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q1FY17</td>
<td>600</td>
</tr>
<tr>
<td>Q2FY17</td>
<td>700</td>
</tr>
<tr>
<td>Q3FY17</td>
<td>800</td>
</tr>
<tr>
<td>Q4FY17</td>
<td>1,000</td>
</tr>
<tr>
<td>Q1FY18</td>
<td>1,200</td>
</tr>
</tbody>
</table>

% growth since Q1FY17

- Q1FY17: 0%
- Q2FY17: 10%
- Q3FY17: 20%
- Q4FY17: 40%
- Q1FY18: 70%

USA growth on Q1FY17
Ellex iTrack™ Sales & Marketing Opportunity

The graph depicts an estimate of the total number of ophthalmologists in each region based on Ellex records. As not all ophthalmologists will use iTrack, this graph shows the relative size of each region, not the absolute size. An individual surgeon engaged and convinced on the safety and efficacy of Ellex iTrack™ and regularly using Ellex iTrack™ may perform anywhere between 3 procedures and 30 procedures per month.

- As of August 2017 there are 12 sales reps and 3 clinical trainers on the ground in the USA
- Targeting additional USA sales representatives and USA clinical trainers and OUS clinical trainers

### ELLEX iTRACK™ PROCEDURES AND OPHTHALMOLOGISTS BY USA SALES REGION

<table>
<thead>
<tr>
<th>Region</th>
<th>No. of Ophthalmologists</th>
<th>No. of Ellex iTrack Procedures FY17</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plains NW</td>
<td>416</td>
<td>122</td>
</tr>
<tr>
<td>Pacific NW</td>
<td>839</td>
<td>253</td>
</tr>
<tr>
<td>New England</td>
<td>879</td>
<td>8</td>
</tr>
<tr>
<td>Midwest</td>
<td>114</td>
<td>102</td>
</tr>
<tr>
<td>Mountain</td>
<td>1353</td>
<td>231</td>
</tr>
<tr>
<td>Great Lakes</td>
<td>1956</td>
<td>64</td>
</tr>
<tr>
<td>Northeast</td>
<td>1997</td>
<td>166</td>
</tr>
<tr>
<td>Mid Atlantic</td>
<td>2284</td>
<td>64</td>
</tr>
<tr>
<td>Central</td>
<td>2712</td>
<td>166</td>
</tr>
<tr>
<td>Southwest</td>
<td>3488</td>
<td>445</td>
</tr>
<tr>
<td>Southeast</td>
<td>3913</td>
<td>445</td>
</tr>
<tr>
<td>West</td>
<td>3977</td>
<td>714</td>
</tr>
</tbody>
</table>

The graph shows the relative size of each region, not the absolute size.
## Ellex iTrack™ - Manufacturing Upgrade Plan

<table>
<thead>
<tr>
<th>Capacity expansion project</th>
<th>Annual capacity in iTrack units</th>
<th>Date capacity available</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage 1 completed July 2017 – cleanroom extension in Fremont</td>
<td>20,000 units</td>
<td>July 2017</td>
</tr>
<tr>
<td>Stage 2 underway Sept 2017 – additional cleanroom at Fremont</td>
<td>Additional 30,000 to 50,000 units</td>
<td>July 2018</td>
</tr>
<tr>
<td>Stage 3 currently in concept-level planning</td>
<td>Additional capacity to achieve a total of at least 100,000 units</td>
<td>December 2019 (est)</td>
</tr>
</tbody>
</table>

### Ellex iTrack™ units sold

<table>
<thead>
<tr>
<th></th>
<th>FY16</th>
<th>FY17</th>
<th>3mths Q1FY18</th>
</tr>
</thead>
<tbody>
<tr>
<td>USA</td>
<td>3,422</td>
<td>4,331</td>
<td>1,485</td>
</tr>
<tr>
<td>Asia</td>
<td>385</td>
<td>1,535</td>
<td>350</td>
</tr>
<tr>
<td>Rest of World</td>
<td>3,049</td>
<td>3,789</td>
<td>1,121</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>6,856</strong></td>
<td><strong>9,655</strong></td>
<td><strong>2,956</strong></td>
</tr>
</tbody>
</table>
Substantial growth opportunity pending results of clinical trial. Unique, patent-protected nano pulse laser that rejuvenates aging retinal cells, thus delaying progression to late stage AMD. Sales to early adopters taking place under CE mark. Ellex has in-place distribution channel to roll Ellex 2RT® out.
Ellex 2RT® - potentially game-changing interventional treatment for early to intermediate AMD

- The thesis behind 2RT, established through preclinical studies, is that AMD patients suffer from an insufficiency of nutrient transport to the highly metabolically demanding retina.

- 2RT is a patented nano-pulse laser that, when applied to the retina, induce re-population of the cellular structure to re-establish sufficient nutrient transport.

- 2RT induced cell repopulation, the subject of peer reviewed scientific publications, is now the subject of a significant masked multicentre study on human subjects ("LEAD" study).

- Provides patients with treatment at an early disease stage where no other treatment exists potentially eliminating the dreaded "watchful waiting".

- Provides doctors with a revenue stream that does not currently exist.

- Ellex will sell Ellex 2RT® through its existing laser and ultrasound distribution channel.

- Marketscope Ophthalmic Lasers 2017 report estimates that approximately 20m people globally have late stage AMD and 153m people have the disease in its early stage.

- Pharmaceutical treatments (Anti VEGF) focussed on the smaller market for late stage state disease

- Estimated annual global spend Anti VEGF is at least US$5.1bn in 2013 and is expected to be $10.1bn by 2023 annually in the 7 major economies (1) in the world

(1) Quoted in Retinal Physician Jan/Feb 2015 edition
Ellex 2RT® Early Adoption under CE Mark & clinical study milestones

Sales being made under CE mark to “early adopter” ophthalmologists in Europe, Australia, New Zealand and Canada for treating patients with early/intermediate age related macular degeneration.

These early adopters provide us with feedback on the safety and efficacy of the product, its operation in a clinical setting and the operation of the per-procedure billing system.

<table>
<thead>
<tr>
<th>Date</th>
<th>Milestones</th>
</tr>
</thead>
<tbody>
<tr>
<td>First quarter CY 2018 (est)</td>
<td>Case study series data on safety and efficacy from early commercial adopters</td>
</tr>
<tr>
<td>May 2018</td>
<td>Final result expected from LEAD clinical trial on 3 year follow up that ends in April 2018</td>
</tr>
<tr>
<td>January 2019</td>
<td>Pending the result of the LEAD Clinical trial, commencement of commercial sales through the laser and ultrasound segment sales channel</td>
</tr>
</tbody>
</table>
LEAD Study – Laser intervention in Early Age related macular Degeneration

• ClinicalTrials.gov identifier: NCT01790802. “A multicentre, randomized trial into the safety and efficacy of Nanosecond Microsurgical Laser Intervention into Early Age-related Macular Degeneration”

• Primary and secondary outcome measures:
  - progression to advance Age-related Macular Degeneration in the treated eye over 36 months (secondary measure is progression in untreated eye)
  - rate of progression to advanced AMD, either CNV or GA or pre-clinical atrophy, in the study eye of treatment group compared to sham procedure group over 36 months (secondary measure in progression in untreated eye)

• Other Measures:
  - reversal of early clinical indicators (drusen area) over 36 months
  - improvements in visual activity over 36 months

• Total 292 patients (eyes) enrolled in two areas in the study:
  - Active Laser procedure and Sham Laser Procedure randomised on 1:1 basis

• Recruitment commenced in November 2012 and 36 month follow up period for last enrolled patient ends in April 2018
• Read out approximately May 2018

Interim LEAD Study results - 18 month interim review in May 2016

Safety:
• There was no meaningful difference in the incidence of neovascularization (Choroidal Neovascularisation) between groups giving reassurance that the 2RT® laser was not leading to any early increase in neovascularization as had appeared to be the case in previous thermal laser trials. There was no meaningful difference in the incidence of geographical atrophy (GA) between groups, thereby giving reassurance that the 2RT® laser was not dramatically increasing the rate of GA.

Potential Efficacy:
• There was a meaningful difference between the two study groups in that one of the two groups demonstrated a reduction in drusen load and an improvement in retinal sensitivity.
Ellex 2RT® Framework for Business Model

Ellex 2RT® may allow physicians to intervene and treat patients at a stage of the disease for which there is no alternative therapy.

- Diagnosis by optometrists routinely taking place with retinal imaging
- Sales to ophthalmologists through the existing laser and ultrasound sales channel
- Doctors purchase the Ellex 2RT® laser and contract to pay an additional fee each time it is used
- Provide recurring revenue that grows with the increase in the installed base
- Purchase contract and per procedure billing arrangements are being successfully trialled and tested with the early adopter sales
The Ellex core business produces laser & ultrasound products that are used daily by ophthalmologists worldwide. Ellex has achieved revenue growth CAGR of 8% over FY2013 to FY2017, this exceeds the market growth rate estimated by Marketscope 2017 Ophthalmic Lasers Report.
Ellex Core Laser & Ultrasound Financial Performance

- The core laser and ultrasound business provides products used everyday by ophthalmologists globally.
- World-leading positions in cataracts and glaucoma lasers.
- CAGR for revenue FY13 to FY17 is 8%.

Ellex has a dominant position in SLT lasers for glaucoma. Recently released and patented “Reflex” technology is expected to drive further growth in market share.

Ellex also has a significant market positions in diagnostic ocular ultrasound and retinal lasers.

Core laser and ultrasound profitability relatively stable.
- Average fully-burdened gross margin percentage greater than 50%.
### Ellex Core Laser & Ultrasound competitive landscape

<table>
<thead>
<tr>
<th>Disease</th>
<th>Current Ellex Devices</th>
<th>Ellex Revenue FY17 A$m</th>
<th>Total annual spend on disease treatment with pharma and devices</th>
<th>Current device-market accessible to Ellex (Total US$550m)</th>
<th>Assessed device-market position against competition</th>
</tr>
</thead>
</table>
| Glaucoma – early stage                | SLT with TangoReflex™, Tango™                                                        | $23m                   | US$4.6 billion$^{(1)}                                           | US$45 million (CAGR 1.5%)$^{(1)}                                    | 1. Ellex$^{(4)}  
2. Lumenis                                           |
| Cataracts and Vitreous Floaters       | Ultra Q™ and Ultra Q Reflex™                                                          | $20m                   | US$3.3 billion plus 25.3 million cataract operations per year$^{(1)} | US$65 million (CAGR 2%$^{(1)} plus more with vitreous floater treatment) | 1. Ellex$^{(4)}  
2. Lumenis  
3. Nidek                                                   |
| Diabetic Disease of Retina            | Integre Pro™ and Integre Pro Scan™ and Solitaire™                                    | $13m                   | US$1.9 billion$^{(2)}                                           | US$283 million (CAGR 2.9%)$^{(1)}                                   | Ellex, Nidek, Lumenis, Topcon & Iridex$^{(5), (4)} |
| Diagnostic Ultrasound                 | Eyecubed™ and Eyeone™                                                                | $9m                    | Included above                                                  | US$157m (CAGR 6%)                                                   | Ellex, Sonomed & Quantel$^{(5)}                        |

$^{(2)}$ “Global Diabetic Retinopathy Market 2015-2019” Technavio Insights  
$^{(3)}$ “Global Market Study on Ophthalmic Devices” Persistence Market Research August 2015  
$^{(4)}$ Assessed by Marketscope 2017 Ophthalmic Lasers Report  
$^{(5)}$ Assessed by Ellex management
Core business growth drivers

Laser Floater Removal with Reflex:
- Proprietary, patented Ellex Ultra Q Reflex™ and Ellex Tango Reflex™ lasers are the world’s first and only ophthalmic laser designed for the treatment of floaters i.e. Laser Floater Removal (LFR). Provides physicians with a treatment for a common condition hitherto treated invasively or not at all.
- Mission for Ellex is to replace the global installed base of 28,000 lasers for secondary cataracts (replacement value US$560m)(1)

Increase market penetration of SLT as a first-line therapy in both developed and developing markets.

SLT:
- Current mainstay of glaucoma treatment is medication (topical drops) but it places a significant burden on patients to comply with a daily medication regimen and continuously pay for the drops.
- A single treatment with Ellex SLT can free a patient from the need for daily drops for up to 10 years.
- Proven efficacy plus good financial returns to physicians.
- SLT will benefit from growth in awareness of MIGS.

Laser Floater Removal performed with Ultra Q Reflex laser is the only outpatient-based, minimally invasive treatment option for floaters.

Estimated Global Penetration of SLT (installed base/number of ophthalmologists) (2)

(1) MarketScope “2017 Ophthalmic Lasers Report”
(2) Combination of Ellex records, MarketScope “2017 Ophthalmic Laser Report” and article in British Journal of Ophthalmologists dated June 2012
Evolving Treatment of Glaucoma – SLT & iTrack™

A new theme – Ellex Tango (SLT) and Ellex iTrack™ (MIGS) – unique offering from a single company

- SLT now recognized as a highly effective first-line therapy (331 papers on SLT per PubMed - US National Library of Medicine)
- SLT can function as a diagnostic indicator of a patient’s pathology i.e. If SLT is effective, the primary region of obstruction lies within trabecular meshwork
- SLT does not affect outcomes of future surgery or medication use - can be used earlier in treatment paradigm
- SLT stimulates a process of cellular regeneration to create a healthier more porous trabecular meshwork structure; almost completely free of side effects
- ABiC is a restorative minimally invasive glaucoma surgery (MIGS)
- ABiC flushes out natural outflow channels without damaging tissue or leaving behind a stent or shunt
Recap of highlights

- Ellex is a world leader in ophthalmology with number one market share in ophthalmic lasers, a 30+ year operating history and well recognized and trusted global brand
- Ellex has a seasoned senior management team with members showing at least 20 years of experience in the ophthalmic space
- Ellex iTrack™ is a unique, patent-protected micro-catheter for treating glaucoma, manufactured in the United States, currently experiencing 71\(^{(1)}\)% growth in USA sales
- Ellex 2RT® is a potentially game changing, minimally invasive, painless interventional treatment for early to intermediate AMD
- Ellex 2RT® clinical trial data expected mid-2018 from a 6 year sham controlled trial
- Ellex core business produces lasers & ultrasound products that are used daily by ophthalmologists worldwide and has grown at a revenue CAGR of 8\(^{(2)}\) from 2013 to 2017, significantly outpacing the market growth rate of 3\(^{(3)}\).

(1) Q1 fiscal year 2018 compared with Q1 fiscal year 2017
(2) Based on Ellex data
(3) MarketScope “2017 Ophthalmic Lasers Report”